page-decoration REQUEST A REPRESENTATIVE

While oxybate treatments have made a significant impact in treating daytime symptoms,

Twice-nightly oxybates may be placing an additional burden on patients1

Mistimed or missed doses with twice-nightly sodium oxybate present potential risks for patients and may lead to suboptimal clinical outcomes2,3

Dose too early chart Dose too early chart mobile Dose too early chart Dose too early chart mobile Dose too early chart Dose too early chart mobile

*FDA Adverse Reporting System Public Dashboard; incidence or prevalence can't be determined from this reporting system alone due to potential underreporting of events.

References:

  1. References: 1. Dubow J, Avidan AY, Corser B, et al. Preferences for attributes of sodium oxybate treatment: a discrete choice experiment in patients with narcolepsy. Patient Prefer Adherence. 2022;16:937-947. 2. Gudeman J, Burroughs D. Evidence of accidental dosing errors with immediate-release sodium oxybate data from the US Food and Drug Administration adverse event reporting system. Drugs Real World Outcomes. 2023;10(2):225-234. 3. Vrijens B, Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691‐705. 4. XYREM. Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc; 2023. 5. XYWAV. Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc; 2023.